6589 Taikang Bio's Biosimilar Drug 'EIRGASUN vial 420 mg' Approved for National Health Insurance Coverage by NHIA
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
Taikang Bio's (6589) biosimilar drug 'EIRGASUN vial 420 mg' has been approved by Taiwan's National Health Insurance Administration (NHIA) under the Ministry of Health and Welfare for inclusion in National Health Insurance coverage. It is indicated for the treatment of HER2-overexpressing early breast cancer, metastatic breast cancer, and metastatic gastric cancer. The price is NT$24,240 per vial, effective from June 1, 2026.